Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannitol SCHEMBL11015104 | 0.95 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL3909131 | 0.95 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL619756 | 0.95 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL28899433 | 0.90 | LMNA (0.55) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL15060035 | 0.90 | LMNA (0.55) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Ribitol SCHEMBL3904172 | 0.90 | LMNA (0.53) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylitol SCHEMBL20561020 | 0.90 | LMNA (0.53) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL4650185 | 0.88 | LMNA (0.52) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| E968 SCHEMBL578415 | 0.84 | ALDH1A1 (0.43) | LMNAL3MBTL1TDP1KDM4EUSP2 | |
| SCHEMBL15354798 | 0.83 | LMNA (0.52) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2708 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397376-A2 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3389783-B1 | NOVEL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3344644-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024127343-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE 1 (ENPP-1) | SRAVATHI AI TECHNOLOGY PRIVATE LIMITED (IN) | 2024-06-20 | — | — | WO | disclosed |
| US-20240180933-A1 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-06 | — | — | US | disclosed |
| US-20240174605-A1 | ARYLSULFONAMIDES AS OREXIN RECEPTOR AGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2024-05-30 | — | — | US | disclosed |
| US-11992489-B2 | Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4159217-B1 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | NOVARTIS AG (CH) | 2024-05-22 | — | — | EP | disclosed |
| EP-3334745-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024091664-A1 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USES | EMORY UNIVERSITY (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-1003721-A1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LIMITED (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-2000012083-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012466-A1 | FORMAMIDE COMPOUNDS AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012082-A1 | FORMAMIDE COMPOUNDS AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999021859-A1 | AZAOXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | WO | disclosed |
| WO-1999015500-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999010325-A1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998038179-A1 | REVERSE HYDROXAMATE DERIVATIVES AS METALLOPROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-09-03 | — | — | WO | disclosed |
| US-5102882-A | Nootropic agents | NIPPON SHINYAKU CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-4927835-A | ANTIPYRETICS | NIPPON SHINYAKU CO., LTD. (JP) | 1990-05-22 | — | — | US | disclosed |